In 2014, MAPS spun out a individual division to direct analysis and get ready for an eventual FDA software, which it submitted at the conclusion of past calendar year. In early 2024, that offshoot was renamed Lykos Therapeutics. End users can start with smaller sized dosages making use of crystal